Maven Securities LTD Biocryst Pharmaceuticals Inc Transaction History

Maven Securities LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$4.98 - $6.77 $448,200 - $609,300	90,000 New	90,000 $539,000
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $479,050 - $884,650	-65,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$3.37 - $8.61 $219,050 - $559,650	65,000 New	65,000 $488,000
Q3 2020 Nov 13, 2020	SELL	$3.43 - $5.53 $514,500 - $829,500	-150,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $285,000 - $841,500	150,000 New	150,000 $714,000
Q1 2020 May 15, 2020	SELL	$1.6 - $4.11 $1.79 Million - $4.6 Million	-1,118,593 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $1.78 Million - $3.86 Million	1,118,593 New	1,118,593 $3.65 Million

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.